TABLE 4:

Clinical summary of patients undergoing allo-BMT

Patient No./Age (y)/Sex	Preconditioning Regimen	MTX	HLA Match	Neurotoxicity (days)	Survival after Neurotoxicity (days)	CSP or FK-506 Level (μg/L)	Presenting Symptoms	Imaging Time (hrs)^*	Blood pressure (mm Hg)			BMT-TM Grade	LDH Level (u/L)
Patient No./Age (y)/Sex	Preconditioning Regimen	MTX	HLA Match	Neurotoxicity (days)	Survival after Neurotoxicity (days)	CSP or FK-506 Level (μg/L)	Presenting Symptoms	Imaging Time (hrs)^*				BMT-TM Grade	LDH Level (u/L)	Baseline	Toxic
1/25/F	Cy 4D, TBI 4D		6/6	17	A	CSP 1367	Seizure	3	130/81	160/144	2	426
2/36/F	Cy 2D, TBI 4D		6/6	14	18	CSP 174	Confusion	28	115/85	167/104	3→4^†	432→1980
3/42/F	Cy 4D, TBI 4D		6/6	78	112	CSP 439	Confused, agitated, hallucinations	8	105/80	150/100	3^†	875
4/43/F	Cy 4D, TBI 4D		6/6	23	8	CSP 260	Seizure	16	92/52	210/130	3^†	1055
5/20/M	Cy 4D, TBI 4D		5/6	151	112	CSP 333	Seizure	3	114/86	130/100	4→3^†	2880→546
6/30/M	Cy 4D, TBI 4D		4/6	55	12	CSP 556	Seizure	3	124/88	120/84	4^†	890
7/49/M	Cy 4D, TBI 4D		6/6	17	A	CSP 324	Seizure	4	124/86	150/95	2	237
8/30/M	Cy 4D, TBI 4D		6/6	480	50	CSP 138	HA	20	140/82	164/106	3^†	900
9/19/M	Cy 2D, TBI 4D	Y	6/6	23	173	CSP 508	Seizure	5	112/70	182/130	3^†	415
10/40/F	Cy 2D, TBI 4D	Y	5/6	151	0	FK NP	Seizure	3	140/90	159/110	4^†	2214
11/46/F	Cy 2D, busulfan 4D		6/6	8	15	CSP 209	Seizure	3	110/70	152/96	3→4^†	240→2680
12/25/F	Cy 2D, busulfan 4D		6/6	75	102	CSP 296	Seizure	11	124/72	150/100	NP	285
13/28/M	Cy 2D, busulfan 4D		6/6	27	373	CSP 1124	Seizure	1.5	126/84	115/85	4	1515
14/43/M	Cy 2D, busulfan 4D		6/6	176	23	CSP 144	Seizure	3	160/90	170/110	3→4^†	718
15/41/M	Cy 2D, busulfan 4D		6/6	5	A	CSP 377	Seizure	4	120/70	168/98	NP	143
16/42/F	Cy 2D, TBI 4D, thiotepa 1D	Y	6/6	27	A	CSP 1128	Seizure	5	132/88	140/95	3	204
17/26/F	Cy 2D, TBI 4D, thiotepa 1D	Y	6/6	26	64	CSP 301	Seizure	3	138/100	140/100	NP	283
18/38/F	Cy 2D, thiotopa 3D, busulfan 3D	Y	6/6	16	4	CSP 302	Vision loss, HA	2	150/88	180/100	3	222
19/25/M	Cy 2D, TBI 4D, thiotepa 1D		4/6	23	33	FK 5.7	Vision loss then seizure	1	125/70	165/100	3	1125
20/17/F	Cy 2D, TBI 4D	Y	6/6	17	392	CSP 330	Seizure	18	110/60	120/80	1→3	1179
21/40/F	BEAM	Y	6/6	27	115	FK 2.7	Seizure	6	108/60	114/64	2	2495

Note.—MTX indicates methotrexate; CSP, cyclosporine; LDH, lactate dehydrogenase; D, number of days of regimen; HA, ?; Y, yes; NP, not performed; A, alive survivor.
* Time after patient presentation with symptoms that imaging study was performed.
† Patient undergoing apheresis for BMT-TM.